 


Myla Lai-Goldman | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Myla Lai-GoldmanCEO at GeneCentric Therapeutics, IncLocationRaleigh-Durham, North Carolina AreaIndustryBiotechnologyCurrentGeneCentric Therapeutics, Inc, Hatteras Venture Partners, Personalized Science, LLCPreviousGeneCentric Diagnostics, Inc., LabCorpEducationColumbia University College of Physicians and SurgeonsRecommendations1 person has recommended MylaWebsitesCompany Website500+ connectionsView Myla’s full profile. It's free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Myla’s Full ProfileSummaryDr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics, Inc.  She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. . She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pensylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.ExperienceChief Executive OfficerGeneCentric Therapeutics, IncMay 2017  –  Present (3 months)Venture PartnerHatteras Venture PartnersAugust 2011  –  Present (6 years)Managing PartnerPersonalized Science, LLCJanuary 2009  –  Present (8 years 7 months)Chief Executive OfficerGeneCentric Diagnostics, Inc.June 2011  –  May 2017 (6 years)Executive VP, CMO & CSOLabCorp1990  –  2008 (18 years)SkillsDiagnosticsHardware DiagnosticsInfectious DiseasesBiotechnologyOncologyPersonalized MedicineGenomicsLifesciencesCancerCommercializationImmunologyMolecular BiologyClinical DevelopmentDrug DevelopmentTechnology TransferSee 35+Drug DiscoveryPharmaceutical IndustryBiopharmaceuticalsHealthcareGeneticsBiochemistryMedical DevicesClinical TrialsMolecular DiagnosticsProduct LaunchBioinformaticsFDAR&DStrategyLaboratoryVenture CapitalClinical ResearchMedicineRegulatory AffairsVaccinesCROCorporate DevelopmentTechnology EvaluationLicensingStrategic AlliancesScienceGlobal MarketingHematologyAssay DevelopmentVenture FinancingMarket DevelopmentMicrobiologyCardiologyAngel InvestingCell BiologySee lessHow's this translation?Great•Has errorsThanks for your help!EducationColumbia University College of Physicians and SurgeonsDoctor of Medicine (MD)Doctor of Medicine (MD)1979  –  1983University of PennsylvaniaBachelor of Arts (B.A.), Biology, Concentration in EcologyBachelor of Arts (B.A.), Biology, Concentration in Ecology1975  –  1979RecommendationsA preview of what LinkedIn members have to say about Myla:Myla is an incredible individual and is mutli-talented. She's a true scientific leader and I have always enjoyed working with her. Look for great advancements from any organization that Myla is associated with.See moreSee lessSign up to see who recommended MylaGroupsPersonalized MedicineBoard of Directors (TGL)Molecular Med Tri-ConGlobal Initiative Against HPV & Cervical Cancer (GIAHC) and NCCCBiomarker Research and DevelopmentView Myla’s full profile to...See who you know in commonGet introducedContact Myla directlyView Myla’s Full ProfileNot the Myla you’re looking for? View moreView this profile in another languageEnglishGermanPeople Also ViewedMichelle Albin, DVMPublic Health VeterinarianDavid DeliaCFO at NMS LabsAmanda KizerBrett CaponeStudent at University of North Carolina at Chapel HillBen MillerChief Operating Officer at LabCorp DiagnosticsJoshua UronisClinical Development Scientist, GeneCentric DiagnosticsCharity HowellMarketing SpecialistJeff TerrellHatteras Venture PartnersJune Almenoff MD, PhD, FACPBiopharma Consultant, Board Director, Former President & CMO, Furiex(acquired by Allergan)Tara MartinezDirector, Laboratory Operations at Epic SciencesPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Myla Lai-GoldmanFirst NameLast NameExample:  Myla Lai-GoldmanDr. Myla Lai-GoldmanManaging PartnerUnited StatesMore professionals named Myla Lai-GoldmanLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country




















 


Myla Lai-Goldman | Professional Profile
 


























 









LinkedIn



















































Main content starts below.




Myla Lai-GoldmanCEO at GeneCentric Therapeutics, IncLocationRaleigh-Durham, North Carolina AreaIndustryBiotechnologyCurrentGeneCentric Therapeutics, Inc, Hatteras Venture Partners, Personalized Science, LLCPreviousGeneCentric Diagnostics, Inc., LabCorpEducationColumbia University College of Physicians and SurgeonsRecommendations1 person has recommended MylaWebsitesCompany Website500+ connectionsView Myla’s full profile. It's free!Your colleagues, classmates, and 500 million other professionals are on LinkedIn.View Myla’s Full ProfileSummaryDr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics, Inc.  She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. . She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pensylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.ExperienceChief Executive OfficerGeneCentric Therapeutics, IncMay 2017  –  Present (3 months)Venture PartnerHatteras Venture PartnersAugust 2011  –  Present (6 years)Managing PartnerPersonalized Science, LLCJanuary 2009  –  Present (8 years 7 months)Chief Executive OfficerGeneCentric Diagnostics, Inc.June 2011  –  May 2017 (6 years)Executive VP, CMO & CSOLabCorp1990  –  2008 (18 years)SkillsDiagnosticsHardware DiagnosticsInfectious DiseasesBiotechnologyOncologyPersonalized MedicineGenomicsLifesciencesCancerCommercializationImmunologyMolecular BiologyClinical DevelopmentDrug DevelopmentTechnology TransferSee 35+Drug DiscoveryPharmaceutical IndustryBiopharmaceuticalsHealthcareGeneticsBiochemistryMedical DevicesClinical TrialsMolecular DiagnosticsProduct LaunchBioinformaticsFDAR&DStrategyLaboratoryVenture CapitalClinical ResearchMedicineRegulatory AffairsVaccinesCROCorporate DevelopmentTechnology EvaluationLicensingStrategic AlliancesScienceGlobal MarketingHematologyAssay DevelopmentVenture FinancingMarket DevelopmentMicrobiologyCardiologyAngel InvestingCell BiologySee lessHow's this translation?Great•Has errorsThanks for your help!EducationColumbia University College of Physicians and SurgeonsDoctor of Medicine (MD)Doctor of Medicine (MD)1979  –  1983University of PennsylvaniaBachelor of Arts (B.A.), Biology, Concentration in EcologyBachelor of Arts (B.A.), Biology, Concentration in Ecology1975  –  1979RecommendationsA preview of what LinkedIn members have to say about Myla:Myla is an incredible individual and is mutli-talented. She's a true scientific leader and I have always enjoyed working with her. Look for great advancements from any organization that Myla is associated with.See moreSee lessSign up to see who recommended MylaGroupsPersonalized MedicineBoard of Directors (TGL)Molecular Med Tri-ConGlobal Initiative Against HPV & Cervical Cancer (GIAHC) and NCCCBiomarker Research and DevelopmentView Myla’s full profile to...See who you know in commonGet introducedContact Myla directlyView Myla’s Full ProfileNot the Myla you’re looking for? View moreView this profile in another languageEnglishGermanPeople Also ViewedMichelle Albin, DVMPublic Health VeterinarianDavid DeliaCFO at NMS LabsAmanda KizerBrett CaponeStudent at University of North Carolina at Chapel HillBen MillerChief Operating Officer at LabCorp DiagnosticsJoshua UronisClinical Development Scientist, GeneCentric DiagnosticsCharity HowellMarketing SpecialistJeff TerrellHatteras Venture PartnersJune Almenoff MD, PhD, FACPBiopharma Consultant, Board Director, Former President & CMO, Furiex(acquired by Allergan)Tara MartinezDirector, Laboratory Operations at Epic SciencesPublic profile badgeInclude this LinkedIn profile on other websitesView profile badgesFind a different Myla Lai-GoldmanFirst NameLast NameExample:  Myla Lai-GoldmanDr. Myla Lai-GoldmanManaging PartnerUnited StatesMore professionals named Myla Lai-GoldmanLinkedIn member directory:abcdefghijklmnopqrstuvwxyzmoreBrowse members by country









































 


Myla Lai-Goldman | Berufsprofil
 





























 









LinkedIn



















































Main content starts below.




Teile dieses Profils können maschinell übersetzt werden. Die Übersetzung kann Fehler enthalten.          Übersetzung anzeigen.Original anzeigen.AblehnenMyla Lai-GoldmanCEO at GeneCentric Therapeutics, IncStandortRaleigh-Durham und Umgebung, North CarolinaBrancheBiotechnologieAktuellGeneCentric Therapeutics, Inc, Hatteras Venture Partners, Personalized Science, LLCFrüherGeneCentric Diagnostics, Inc., LabCorpAusbildungColumbia University College of Physicians and SurgeonsEmpfehlungen1 Person hat Myla Lai-Goldman empfohlenWebseitenUnternehmenswebseite500+KontakteSehen Sie sich Myla Lai-Goldmans vollständiges Profil an. Es ist kostenlos.Ihre Kollegen, Kommilitonen und 500 Millionen weitere Fach- und Führungskräfte sind bereits auf LinkedIn.Myla Lai-Goldmans vollständiges Profil anzeigenZusammenfassungDr. Lai-Goldman is the Chief Executive Officer and President of GeneCentric Therapeutics, Inc.  She is also a founder and director of the Company. Dr. Lai-Goldman spent more than 18 years at Laboratory Corporation of America, Holdings (LabCorp), the last 10 years as Executive Vice President, Chief Medical Officer and Chief Scientific Officer. . She served on LabCorp’s Executive and Management Committees, with strategic and operations responsibilities for 3 major genomic laboratories comprising more than 700 people. During her tenure at the Company, she led all clinical, scientific and medical activities, including the introduction of more than 400 clinical assays. Her experience includes the development of partnerships, licensing, and acquisitions. After leaving LabCorp, Dr. Lai-Goldman became a Venture Partner at Hatteras Venture Partners and is the managing partner of Personalized Science, LLC, a consulting company founded to assist customers achieve successful adoption of innovative diagnostics. Dr. Lai-Goldman received her BS from the University of Pensylvania and MD from Columbia University College of Physicians and Surgeons. Dr. Lai-Goldman is Board-certified in anatomic and clinical pathology.ErfahrungChief Executive OfficerGeneCentric Therapeutics, IncMai 2017  –  Heute (3 Monate)Venture PartnerHatteras Venture PartnersAugust 2011  –  Heute (6 Jahre)Managing PartnerPersonalized Science, LLCJanuar 2009  –  Heute (8 Jahre 7 Monate)Chief Executive OfficerGeneCentric Diagnostics, Inc.Juni 2011  –  Mai 2017 (6 Jahre)Executive VP, CMO & CSOLabCorp1990  –  2008 (18 Jahre)dummy1dummy2Original anzeigenÜbersetzung anzeigenKenntnisseDiagnostikDiagnosticsHardwarediagnoseHardware DiagnosticsInfektionskrankheitenInfectious DiseasesBiotechnologieBiotechnologyOnkologieOncologyPersonalisierte MedizinPersonalized MedicineGenomikGenomicsLifesciencesKrebsCancerVermarktungCommercializationImmunologieImmunologyMolekularbiologieMolecular BiologyKlinische EntwicklungClinical DevelopmentArzneimittelentwicklungDrug DevelopmentTechnologietransferTechnology Transfer35+ anzeigenPharmaforschungDrug DiscoveryPharmaindustriePharmaceutical IndustryBiopharmazeutikaBiopharmaceuticalsGesundheitspflegeHealthcareGenetikGeneticsBiochemieBiochemistryMedizinprodukteMedical DevicesKlinische StudienClinical TrialsMolekulardiagnostikMolecular DiagnosticsProdukteinführungProduct LaunchBioinformatikBioinformaticsLebensmittelüberwachungFDAForschung und EntwicklungR&DStrategisches ManagementStrategyLabormedizinLaboratoryRisikokapitalVenture CapitalKlinische ForschungClinical ResearchMedizinMedicineArzneimittelzulassungRegulatory AffairsImpfstoffeVaccinesCROUnternehmensentwicklungCorporate DevelopmentTechnologiebewertungTechnology EvaluationLizenzierungLicensingStrategische AllianzenStrategic AlliancesWissenschaftScienceGlobales MarketingGlobal MarketingHämatologieHematologyAssay-EntwicklungAssay DevelopmentRisikofinanzierungVenture FinancingMarktentwicklungMarket DevelopmentMikrobiologieMicrobiologyKardiologieCardiologyBusiness AngelAngel InvestingZellbiologieCell BiologyWeniger anzeigenWie finden Sie diese Übersetzung?Gut•FehlerhaftDanke für Ihre Hilfe!AusbildungColumbia Universität College of Physicians and SurgeonsColumbia University College of Physicians and SurgeonsOriginal anzeigenÜbersetzung anzeigenWie finden Sie diese Übersetzung?Gut•FehlerhaftDanke für Ihre Hilfe!Doctor of Medicine (MD)Doctor of Medicine (MD)1979  –  1983Universität PennsylvaniaUniversity of PennsylvaniaOriginal anzeigenÜbersetzung anzeigenWie finden Sie diese Übersetzung?Gut•FehlerhaftDanke für Ihre Hilfe!Bachelor of Arts (B.A.), Biology, Concentration in EcologyBachelor of Arts (B.A.), Biology, Concentration in Ecology1975  –  1979EmpfehlungenHier ein kleiner Vorgeschmack darauf, was LinkedIn Mitglieder über Myla Lai-Goldman sagen:Myla is an incredible individual and is mutli-talented. She's a true scientific leader and I have always enjoyed working with her. Look for great advancements from any organization that Myla is associated with.Mehr anzeigenWeniger anzeigenLoggen Sie sich ein, um zu sehen, wer Myla Lai-Goldman empfohlen hat.GruppenPersonalized MedicineBoard of Directors (TGL)Molecular Med Tri-ConGlobal Initiative Against HPV & Cervical Cancer (GIAHC) and NCCCBiomarker Research and DevelopmentSehen Sie sich Myla Lai-Goldmans vollständiges Profil an. Finden Sie heraus, welche gemeinsamen Kontakte Sie habenLassen Sie sich vorstellenKontaktieren Sie Myla Lai-Goldman direktMyla Lai-Goldmans vollständiges Profil anzeigenDas ist nicht die Person mit dem Namen Myla Lai-Goldman, die Sie gesucht haben? Mehr anzeigenProfil in einer anderen Sprache anzeigenEnglischDeutschEbenfalls angesehenMichelle Albin, DVMPublic Health VeterinarianDavid DeliaCFO at NMS LabsAmanda KizerBrett CaponeStudent at University of North Carolina at Chapel HillBen MillerChief Operating Officer at LabCorp DiagnosticsJoshua UronisClinical Development Scientist, GeneCentric DiagnosticsCharity HowellMarketing SpecialistJeff TerrellHatteras Venture PartnersJune Almenoff MD, PhD, FACPBiopharma Consultant, Board Director, Former President & CMO, Furiex(acquired by Allergan)Tara MartinezDirector, Laboratory Operations at Epic SciencesBadge für Ihr öffentliches ProfilDieses LinkedIn Profil auf anderen Webseiten verwendenProfil-Badges anzeigenWeitere Personen namens Myla Lai-Goldman suchenVornameNachnameBeispiel:  Myla Lai-GoldmanDr. Myla Lai-GoldmanManaging PartnerVereinigte StaatenWeitere Personen namens Myla Lai-GoldmanLinkedIn Mitgliederverzeichnis:abcdefghijklmnopqrstuvwxyzMehrMitglieder nach Land durchsuchenBeginn der UmfrageSchließenErweiternWas halten Sie von dieser Übersetzung?Helfen Sie dabei, die maschinell übersetzten Profile von LinkedIn zu verbessern. Ist Ihnen einer dieser Punkte aufgefallen?       Falsches GeschlechtUnprofessioneller StilFormatierungsfehlerFehlerhafte ÜbersetzungWählen Sie bitte mindestens eine Antwort aus.Feedback sendenEnde der UmfrageBeginn des DialogsSchließenDanke für Ihre Hilfe.Wir verwenden diese Informationen zur Verbesserung unserer maschinellen Übersetzungen.Ende des Dialogs









































 



 Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors 
         










    










 






 











 









Sequenom Welcomes Myla Lai-Goldman, M.D., To Board Of Directors

Sep 04, 2012, 07:00 ET
		  		  						
						 from   Sequenom, Inc. 











 
















































 

 















































 

 

 
 
 
 







SEQUENOM logo.  (PRNewsFoto/Sequenom, Inc.)    
 Facebook
 Twitter
 Pinterest

































 




 




SEQUENOM logo.  (PRNewsFoto/Sequenom, Inc.)
 


 

 




 





 


SAN DIEGO, Sept. 4, 2012 /PRNewswire/ -- Sequenom, Inc. (NASDAQ:   SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced the appointment of Myla Lai-Goldman, M.D., to its Board of Directors, effective September 11, 2012. Dr. Lai-Goldman has also been appointed to the Science Committee of the Company's Board of Directors.
Dr. Lai-Goldman is a managing partner at Personalized Science, LLC, and Chief Executive Officer of GeneCentric Diagnostics, Inc. and a Venture Partner with Hatteras Venture Partners. She previously served as Executive Vice President, Chief Medical Officer and Chief Scientific Officer of Laboratory Corporation of America.  She is a recognized author and speaker on clinical diagnostics, including factors that lead to successful adoption of novel technologies. 
"We welcome Dr. Lai-Goldman to our board, and look forward to her contributions as a renowned voice in the pathology community to add strategic counsel to our short-term and long-term growth efforts in the diagnostics market," said Harry F. Hixson, Jr., Ph.D., Chairman and CEO, Sequenom, Inc. 
Dr. Lai-Goldman received her undergraduate degree in biology from the University of Pennsylvania and her medical degree from Columbia University. She completed a pathology residency and surgical pathology fellowship at UCLA in Los Angeles, and followed with a hematopathology fellowship at the University of North Carolina at Chapel Hill. 
"As we continue to advance our role in driving forward the clinical applications of genetic technologies, Dr. Lai-Goldman's extensive experience in clinical laboratory medicine and specifically in molecular diagnostics will be extremely insightful and contribute meaningfully to the Board's Science Committee," said Ronald M. Lindsay, Ph.D., Executive Vice President, Research and Development at Sequenom. 
About Sequenom
Sequenom, Inc. (NASDAQ:   SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site. 
Forward-Looking Statements 
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company's expectations regarding Dr. Lai-Goldman's contributions to the Company,  the Company's short-term and long-term  growth efforts in the diagnostics market, and the Company's intentions and ability to continue to advance its role in driving forward the clinical applications of genetic technologies, are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market demand for and acceptance and use of the Company's technology and tests such as the MaterniT21 PLUS test, reliance upon the collaborative efforts of other parties, the Company or third parties obtaining or maintaining regulatory approvals that impact the Company's business, government regulation particularly with respect to diagnostic products and laboratory developed tests, publication processes, the performance of designed product enhancements, the Company's ability to develop and commercialize technologies and products, particularly new technologies such as noninvasive prenatal diagnostics, laboratory developed tests, and genetic analysis platforms, the Company's financial position, the Company's ability to manage its existing cash resources or raise additional cash resources, competition, intellectual property protection and intellectual property rights of others litigation involving the Company, and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission, including without limitation its Quarterly Report on Form 10-Q for the quarter ended June 30, 2012 and its Annual Report on Form 10-K for the year ended December 31, 2011. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.
(Logo: http://photos.prnewswire.com/prnh/20040415/SQNMLOGO) 
 SOURCE  Sequenom, Inc.  

RELATED LINKS
http://www.sequenom.com



  

 View Table Fullscreen 




  View Table Fullscreen 





Journalists and Bloggers
The news you need, when you need it.
 
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.
LEARN MORE




 

 
 



















































  
















Sep 05, 2012, 07:00 ET
Preview: Sequenom Announces Participation At The Morgan Stanley Global Healthcare Conference




















Aug 28, 2012, 07:00 ET
Preview: Sequenom Completes International Distribution Agreements To Expand Access To MaterniT21 PLUS Prenatal Testing Service








My News


  Release contains wide tables.	  View fullscreen.





Looking to send a news release with PR Newswire?
Take advantage of the world's leading distribution platform.
Sign up to get started
Request more information
Have an account? Log In

 















Search











Searching for your content...









Advanced Search












































 


  






Myla Lai-Goldman, CEO, GeneCentric Diagnostics


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Myla Lai-Goldman



CEO
at
GeneCentric Diagnostics


Location: Durham, NC





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Myla Lai-Goldman



CEO
at
GeneCentric Diagnostics


Location: Durham, NC




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Dr. Myla Lai-Goldman has over 20 years experience in the development, commercialization and adoption of novel molecular diagnostic assays. In 2011, with Drs. Chuck Perou and Neil Hayes of the University of North Carolina at Chapel Hill, she co-founded GeneCentric Diagnostics, a Hatteras Fund IV company, whose initial product, the Lung Subtype Platform (LSPTM) enables oncologists make more informed treatment decisions for their lung cancer patients.
Until her retirement on December 31, 2008, Myla was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America® Holdings (LabCorp®), where she managed LabCorp’s National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. From 1998 until April 2008, Myla also served as Chief Scientific Officer of the company, where she was responsible for R & D. Until 2006, she managed the operations of the Company’s Center for Molecular Biology and Pathology in Research Triangle Park, NC; National Genetics Institute, Inc. in Los Angeles, CA; and ViroMed Laboratories, Inc. in Minneapolis, MN. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Myla joined the Company in 1990.
Myla earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke’s Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.
Community and Board Engagements:
Myla serves on the Executive Committee of the Board of Directors for The Medical Foundation of North Carolina. Myla also serves on the Board of Directors of Sequenom.



2

Companies in Career





N/A

Related Markets





1

Colleagues





N/A

Related Investments








Alias
N/A



Industry
Venture Capital




Tags
Venture Capital, Private Equity




Topics of Influence












N/A







N/A
























Careers








Achievements








Investments








Related People






 Edit
View all 



Myla Lai-GoldmanCareer (2)











GeneCentric Diagnostics



CEO












Hatteras Venture Partners



Venture Partner








Competencies










 Edit
View all 



Myla Lai-GoldmanEducation (2)










University of Pennsylvania













Columbia University












 Edit



Myla Lai-GoldmanAchievements and Recognitions





Add Milestone


No milestones has been recorded for Myla Lai-Goldman






 Edit



Myla Lai-GoldmanLinks





Add Link


No links has been recorded for Myla Lai-Goldman









Myla Lai-GoldmanInvestments/Acquisitions





No investments has been recorded for Myla Lai-Goldman









Myla Lai-GoldmanInvestments Representing Others





No investment reps has been recorded for Myla Lai-Goldman








Myla Lai-GoldmanRelated People








Colleagues at GeneCentric Diagnostics







Mark R. Miglarese

CSO













View all 



Myla Lai-GoldmanRecommended Market Profiles (8)








Telemedicine

10,000 or More employees
19 companies








Social Media Marketing (ChiefMartec.com)

5,000 - 10,000 employees
111 companies








Big Data Universe List of Lists

10,000 or More employees
533 companies








Aggregated Marketing Technology

10,000 or More employees
2650 companies








Shared Economy Landscape (Jeremiah Owyang)

10,000 or More employees
267 companies








Inside Sales Landscape

10,000 or More employees
641 companies




















Myla P. Lai-Goldman Ph.D., M.D.: Executive Profile & Biography - Bloomberg









































  





















































































July 22, 2017 1:18 PM ET
Biotechnology

Company Overview of GeneCentric Therapeutics, Inc.



SnapshotPeople 




OverviewBoard MembersCommittees



Executive Profile
Myla P. Lai-Goldman Ph.D., M.D.Chief Executive Officer, President and Director, GeneCentric Therapeutics, Inc.AgeTotal Calculated CompensationThis person is connected to 6 Board Members in 6 different organizations across 12 different industries.See Board Relationships59--
Background

		Dr. Myla P. Lai-Goldman, M.D., Ph.D., is a Venture Partner of Hatteras Venture Partners. Dr. Lai-Goldman co-founded and serves as the Chief Executive Officer and President of GeneCentric Diagnostics, Inc. She served as Scientific Advisor of Seventh Sense Biosystems, Inc. She is Managing Partner at Personalized Science, LLC. She served as the Chief Executive Officer, Chief Medical Officer and Chief Scientific Officer at CancerGuide Diagnostics, Inc. She served as an Executive ... Vice President at Medical World Communications, Inc. She has deep experience in transitioning research-based technologies into clinical medicine. She served as the Chief Scientific Officer, Executive Vice President and Medical Director of Laboratory Corp. of America Holdings from April 1998 to December 31, 2008 and also served as its Chief Medical Officer until December 31, 2008, Consultant from December 31, 2008 to April 30, 2009 and Senior Vice President since 1997, where she was responsible for R&D. She served as a Member of The Scientific Advisory Board at TetraLogic Pharmaceuticals Corporation (TetraLogic Pharmaceuticals, Inc) and served as its Clinical Advisor. She managed the Center for Molecular Biology and Pathology at Laboratory Corp. of America Holdings’s Research Triangle Park, NC facility; National Genetics Institute, Inc.; and Viro-Med Laboratories, Inc. Additionally, she held the position of Medical Director for the Center for Molecular Biology and Pathology from 1991 to 2005. Dr. Lai-Goldman joined RBL in 1990. During her tenure at LabCorp, she managed LabCorp's National Office of Quality and Science through which she was responsible for all quality, science and medical activities for it and its subsidiaries. She serves as a Member of Scientific Advisory Board at GenVault Corporation, CanDiag, Inc., and Stemina Biomarker Discovery, Inc. She has been a Director of West Pharmaceutical Services, Inc. since February 2014 and Qvella Corporation. She serves as a Director of Expression Analysis, Inc. and GeneCentric Diagnostics, Inc. She serves as a Member of Scientific Advisory Board at Cypher Genomics inc. She served as a Director of Sequenom Inc. since September 11, 2012 until September 7, 2016. She has over 25 years experience in the development, commercialization and adoption of novel molecular diagnostic assays. She is Board Certified in Anatomic and Clinical Pathology. She received her Medical Degree (MD) from the College of Physicians and Surgeons at Columbia University in New York. She completed a Pathology Residency and Surgical Pathology Fellowship at UCLA in Los Angeles. She completed Postgraduate Training in Internal Medicine at St Luke's Hospital in New York, Anatomic and Clinical Pathology at the UCLA Center for Health Sciences and Hematopathology at the University of North Carolina at Chapel Hill. Dr. Lai-Goldman received her Undergraduate Degree in Biology from the University of Pennsylvania.Read Full Background




Corporate Headquarters
79 TW Alexander DriveResearch Triangle Park, North Carolina 27709United StatesPhone: 919-973-6544Fax: --
Board Members Memberships
DirectorExpression Analysis, Inc.Chief Executive Officer, President and DirectorGeneCentric Therapeutics, Inc.2014-PresentDirectorWest Pharmaceutical Services, Inc.
Education
Post-Doctoral Training University Of North Carolina At Chapel HillMD Columbia UniversityBachelor's Degree University of Pennsylvania
Other Affiliations
Laboratory Corporation of America HoldingsMedical World Communications, Inc.Sequenom Inc.West Pharmaceutical Services, Inc.University Of North Carolina At Chapel HillColumbia UniversityUniversity of PennsylvaniaExpression Analysis, Inc.GenVault CorporationHatteras Venture PartnersTetraLogic Pharmaceuticals CorporationStemina Biomarker Discovery, Inc.Seventh Sense Biosystems, Inc.CancerGuide Diagnostics, Inc.OncoTAb, Inc.Cypher Genomics, Inc.


Annual Compensation
				There is no Annual Compensation data available.
				Stocks Options
				There is no Stock Options data available.
				Total Compensation
				There is no Total Compensation data available.
			



Request Profile Update
















 












The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking 
	here.




Stock Quotes


Market data is delayed at least 15 minutes.







Company Lookup



COMPETITOR COMPENSATIONThere is no Competitor Compensation data available.










Sponsored Financial Commentaries

Sponsored Links






Browse Companies
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
 | 
0
1
2
3
4
5
6
7
8
9






Request Profile Update

						Only a company representative may request an update for the company profile. Documentation will be required.
					  
To contact GeneCentric Therapeutics, Inc., please visit .  Company data is provided by S&P Global Market Intelligence.  Please use this form to report any data issues.
					  


Information Missing - Please enter your information in the following field(s): 




Company Name

Your Name*

Your E-Mail Address*

Your Phone Number*

Type of Data*


Overview
Executives
Key developments
Similar companies
Transactions


Update Needed*

All data changes require verification from public sources.  Please include the correct value or values and a source where we can verify.


Cancel


Submit






Your requested update has been submitted
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.


Close





























WST Myla P. Lai-Goldman Insider Trades for West Pharmaceutical Services Inc.


































Bulletin






Investor Alert





















Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close






Expand
Keep Open
Close































West Pharmaceutical Services Inc.

                  NYSE: WST
          



GO



Set Alerts
Find a Broker




Join TD Ameritrade




Market Index


 

Overview
      
Profile
      
News
      
Charts
      
Financials
      
Historical Quotes
      
Analyst Estimates
      
Options
      
SEC Filings
      
Insiders
      


/marketstate/country/us

West Pharmaceutical Services Inc.



After Hours
 --Quotes are delayed by 20 min
Jul 21, 2017, 4:27 p.m.


WST

/quotes/zigman/131338/composite


$
93.00




Change

0.00
0.00%

Volume
Volume 3,214
Quotes are delayed by 20 min








/quotes/zigman/131338/composite
Previous close

$
			93.48
		


$
				93.00
			
Change

-0.48
-0.51%





Day low
Day high
$92.41
$93.80










52 week low
52 week high

            $70.17
        

            $99.91
        


















Insider Activity


Individual




Myla P. Lai-Goldman



Dr. Myla P. Lai-Goldman, MD, is President, Chief Executive Officer & Director at GeneCentric Diagnostics, Inc., Chief Executive & Scientific Officer at CancerGuide Diagnostics, Inc., and Venture Partner at Hatteras Venture Partners. In 2009, she founded and became the managing partner of Personalized Science, LLC, a consulting company whose mission is to assist its customers achieve successful adoption of innovative diagnostics with actionable results for patient's unmet medical needs. In 2011, with Drs. Chuck Perou and Neil Hayes of the University of North Carolina at Chapel Hill, she co-founded GeneCentric Diagnostics, focused on the development and commercialization of novel molecular diagnostic assays that enable oncologists and their patients make more informed, individualized treatment decisions.
Until her retirement on December 31, 2008, Dr. Lai-Goldman, M.D. was Executive Vice President, Chief Medical Officer of Laboratory Corporation of America Holdings (LabCorp), where she managed LabCorp's National Office of Quality and Science, through which she was responsible for all quality, science and medical activities for LabCorp and its subsidiaries. From 1998 until April 2008, she also served as Chief Scientific Officer of the company, where she was responsible for R & D.
Dr. Lai-Goldman earned an MD from the College of Physicians and Surgeons at Columbia University in New York, and completed postgraduate training in Internal Medicine at St Luke's Hospital in New York, anatomic and clinical pathology at the UCLA Center for Health Sciences, and hematopathology at the University of North Carolina at Chapel Hill. She is board-certified in anatomic and clinical pathology.



Transactions


Date
Shares
Transaction
Value





05/02/2017
1,697


 
Award at $0 per share.


0


05/03/2016
2,262


 
Award at $0 per share.


0


05/05/2015
2,448


 
Award at $0 per share.


0


05/06/2014
3,016


 
Award at $0 per share.


0





        Copyright 2017 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
    











            Officers and Executives
        





Mr. Patrick J. Zenner 
Non-Executive Chairman




Mr. Eric Mark Green 
President, Chief Executive Officer & Director




Mr. David A. Montecalvo 
SVP-Global Operations & Supply Chain




Mr. William J. Federici 
Chief Financial Officer & Senior Vice President




Mr. Eric  Resnick 
Chief Technology Officer & Vice President




Mr. Patrick A. Sim 
Chief Information Officer & Vice President




Mr. Donald A. McMillan 
Vice President-Enterprise Business Systems




Mr. Chris  Ryan 
Vice President & General Manager-Global Generics




Mr. Mike  Schaefers 
Vice President-Product Management




Dr. Scott  Young 
Vice President-Primary Container Technology




Mr. Graham S Reynolds 
Vice President & General Manager-Global Biologics




Mr. Mike  Treadaway 
VP & General Manager-Contract Manufacturing




Ms. Karen A. Flynn 
Chief Commercial Officer & Senior Vice President




Mr. Heino  Lennartz 
Vice President & General Manager-Global Pharma




Mr. Paolo  Pucci 
Director




Ms. Erin  O’Brien 
Senior Director-Marketing




Mr. Daniel  Malone 
Vice President & Controller




Dr. Quintin John Lai 
Vice President-Corporate Development & Strategy




Ms. Emily Y. Denney 
Head-Global Communications




Ms. Annette F. Favorite 
Chief Human Resources Officer & Senior VP




Mr. George Lloyd Miller 
Secretary, Senior Vice President & General Counsel




Ms. Deborah L. Keller 
Independent Director




Mr. John H. Weiland 
Independent Director




Dr. Myla P. Lai-Goldman 
Independent Director




Dr. William F. Feehery 
Independent Director




Mr. Douglas A. Michels 
Independent Director




Mr. Mark A. Buthman 
Independent Director




Dr. Paula A. Johnson 
Independent Director




Mr. Thomas W. Hofmann 
Independent Director









Trending Tickers


/quotes/zigman/17636479/composite VUZI+15.60%


/quotes/zigman/237947/composite JCP-5.83%


/quotes/zigman/59392505/composite NUGT-2.93%


/quotes/zigman/59386294/composite JNUG-5.94%


/quotes/zigman/65801738/composite TLT+1.11%


X




Powered by














Log In




1:18 PM EDT
July 22, 2017


/marketstate/country/us
New York

	Closed


/marketstate/country/uk
London

	Closed


/marketstate/country/jp
Tokyo

	Closed





/marketstate/country/us
 


/marketstate/country/uk
 


/marketstate/country/jp
 











View All



Latest News

/news/latest
1:13pJared Kushner discloses dozens of additional assets in revised filing
12:51pBitcoin surges as miners avert split for now
12:00pAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
11:49aHow OPEC committee’s coming meeting could make or break oil prices
11:15aA grandfather’s financial advice to his grandchildren
10:39aWhy one analyst calls this the ‘chart of the week, month and potentially year’
10:07aThe cracked benchmark? Why some investors want a new standard for bonds
10:05a7 money-making lessons from the richest man who ever lived
10:03aGE’s stock falls as Jeff Immelt’s 64th and last quarter is another disappointment
10:01aNolan’s cinematic vision in ‘Dunkirk’ is Hollywood’s best defense against Netflix
9:59aAlphabet earnings: A $2.74 billion hit for Google, potential YouTube results for investors
9:58aMicrosoft rides huge tax benefit from failing at smartphones to big earnings beat 
9:53aTrump says he has ‘complete power to pardon’
9:29aChipotle earnings: Media coverage of the latest illness scare will put earnings targets at risk
9:24aExxon earnings: Will stock trade higher on expected second-quarter beat?
9:20aPay TV expected to lose more than a million subscribers in latest quarter 
9:20aQualcomm’s issues go beyond Apple fight
9:20aYogaWorks IPO pulled on valuation concerns, not market conditions
9:18aAmazon’s foray into groceries means more mergers of food companies, experts say
9:00aThis is what should really worry you about stocks
Loading more headlines...




dow

/quotes/zigman/627449/realtime
21,580.07

-31.71
-0.15%





nasdaq

/quotes/zigman/12633936/realtime
6,387.75

-2.25
-0.04%





s&p 500

/quotes/zigman/3870025/realtime
2,472.54

-0.91
-0.04%













Kiosk


1352872800000
1352872800000


The RetireMentors






				Retirement advice from our industry experts
				Our team of financial professionals can help you plan and save 
					for retirement, then 
				live well in it.



/conga/kiosk/retirementors.html
361307




1320411600000
1320616500000


Alerts



/conga/kiosk/alerts.html
310238




1333717800000
1333964100000


Virtual Stock Exchange





Our free stock-market game
				• Trade your virtual portfolio in real time
				• Talk strategies in group discussions
				• Find or create a game that suits you
				• Use our learning center to improve 



/conga/kiosk/games.html
310284




1245657600000
1277280000000


Location Scouts




Housing-market insights from our realty pros
																																																							Plus the latest data from Realtor.com on 21 home markets across the U.S.
• See our complete Real Estate site


/conga/kiosk/real_estate.html
357012




1404799200000
1404799200000


Lazy Portfolios





				Set it and forget it
				Check out the returns on our 8 Lazy Portfolios that are made up 
				of low-cost 
				buy-and-hold index funds.

				• How to create your own Lazy Portfolio


/conga/kiosk/lazy_portfolio.html
313134














MarketWatch.com




Site Index
Topics
Help
Feedback
Newsroom Roster

                    Media Archive
Premium Products
Mobile


Company Info
Code of Conduct
Corrections
Advertising Media Kit
Advertise Locally
Reprints & Licensing
Broker Center

                    Your Ad Choices


Follow MarketWatch


































RSS
Podcasts






WSJ.com
Barron's Online
BigCharts
Virtual Stock Exchange


Financial News London
WSJ.com Small Business
realtor.com
Mansion Global












		Copyright © 2017 MarketWatch, Inc.  All rights reserved.
		By using this site, you agree to the Terms of Service,
        Privacy Policy and Cookie Policy.
	



            Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.
        






MarketWatch Top Stories
Link to MarketWatch's Slice.

15



























































      403 - Access Denied.
    














          Sorry, access denied.
        

          For our users’ safety, profiles can’t be accessed via cloud computing systems. If you believe you’re getting this message in error, please contact us at support@doximity.com.
        



              Need help?
            



              Return to Doximity.com
            











      403 - Access Denied.
    














          Sorry, access denied.
        

          For our users’ safety, profiles can’t be accessed via cloud computing systems. If you believe you’re getting this message in error, please contact us at support@doximity.com.
        



              Need help?
            



              Return to Doximity.com
            











      403 - Access Denied.
    














          Sorry, access denied.
        

          For our users’ safety, profiles can’t be accessed via cloud computing systems. If you believe you’re getting this message in error, please contact us at support@doximity.com.
        



              Need help?
            



              Return to Doximity.com
            











      403 - Access Denied.
    














          Sorry, access denied.
        

          For our users’ safety, profiles can’t be accessed via cloud computing systems. If you believe you’re getting this message in error, please contact us at support@doximity.com.
        



              Need help?
            



              Return to Doximity.com
            







Access Denied

Access Denied
 
You don't have permission to access "http://health.usnews.com/doctors/myla-lai-goldman-649999" on this server.
Reference #18.7f37468.1500743924.5ce2a63


